Kennedy NeuroMed Research Foundation
The Kennedy NeuroMed Research Foundation (business registration number: 850425174RR0001) is a Canadian registered charity focused on advancing research into neurological and neurodegenerative disorders. The organization funds studies investigating the causes, prevention, and treatment of conditions such as Alzheimer’s disease and aggressive cancers, including triple-negative breast cancer (TNBC)[1][2].

Focus areas

The foundation prioritizes neuro-medical research, with an emphasis on innovative diagnostic methods and therapies. A landmark 2016 study published in the Journal of Alzheimer’s Disease proposed a saliva-based test for Alzheimer’s by measuring amyloid-β protein 42 levels, which gained international attention and was featured in the journal’s 20th-anniversary edition[2]. Current initiatives include funding preclinical research on non-toxic compounds to target TNBC cells[2].

Operations

Donors can direct contributions to specific research projects aligned with their interests, a model central to the foundation’s mission[1][4]. Its activities emphasize grassroots engagement, social media outreach, and collaboration with researchers to broaden awareness of neurodegenerative and oncological challenges[3][4].

Note: While similarly named institutions like the Kennedy Krieger Institute’s Center for Neurodevelopmental and Imaging Research (CNIR) in the U.S. exist, they operate independently of this Canadian entity[5].

[1] https://www.thekennedyfoundation.org/what-we-do-1 [2] https://www.thekennedyfoundation.org [3] https://www.charitydata.ca/charity/kennedy-neuromed-research-foundation/850425174RR0001/ [4] https://causes.benevity.org/causes/124-850425174RR0001?lang=en [5] https://www.kennedykrieger.org/research/centers-labs-cores/center-for-neurodevelopmental-and-imaging-research